# Relaxed multi-module round-2 P1-R audit

> Date: 2026-06-21
> Scope: P1 concrete-module boundary follow-up focused on `ASD-0744`.
> Rule: only high-confidence changes supported by first-hand paper evidence, official project assets, or other authoritative first-hand sources are written back to the master list and Notes.

## 本轮结论

本轮关闭 1 条 `06 / 07` 边界记录：

| ID | Title short | Sources checked | Decision | Note action |
|---|---|---|---|---|
| `ASD-0744` | BioGAIP | Crossref DOI abstract `10.64898/2026.05.16.720484`; official bioRxiv API `details/biorxiv/10.64898/2026.05.16.720484/na/json`; official repos `zhangjy859/RAG_tools` and `zhangjy859/BioGAIP_peer_review` | accepted `scientific_object_modules=06` only; keep `primary_module_for_filing=06`; do not add `07` | revised `Notes/06_Life_Sciences/Zhang_2026_BioGAIP_Bioinformatics.md` |

## Evidence summary

### `ASD-0744` BioGAIP: A Scalable, User-Friendly and Robust LLM-Powered Multi-Agent System for Automated Bioinformatics Tasks

- Agent evidence: the Crossref abstract explicitly presents BioGAIP as an `LLM-powered agent` built on an `agent-based client-server architecture`, with dynamic information retrieval, automatic environment configuration, and self-directed design of analysis pipelines.
- `06` evidence: all currently accessible first-hand sources consistently anchor the paper in `bioinformatics tasks`, `large-scale, high-throughput biological data`, `large-scale multi-omics analysis`, `diverse published datasets`, and recapitulation of `established biological insights`. The official bioRxiv API categorizes the record as `bioinformatics`, and the official repos are also framed as BioGAIP infrastructure rather than disease-specific platforms.
- Why `07` is not accepted: no currently accessible first-hand source exposes independent medical / health-science object evidence such as disease-centered case studies, patient-level cohorts, diagnosis, treatment recommendation, prognosis, therapeutic validation, or explicit clinical endpoints. Biomedical references in the bibliography cannot substitute for object-level evidence in BioGAIP's own reported experiments.
- Accepted action: close the `06 / 07` boundary as `06` only. At the current evidence level, BioGAIP is an automated life-science / bioinformatics workflow system, not a confirmed medical-object study.

## Count update

Post-P1-R relaxed overlay counts are unchanged because `ASD-0744` lands as a single-module `06` record:

| Scientific object module | Expanded assignment count |
|---|---:|
| `01` | 55 |
| `02` | 37 |
| `03` | 82 |
| `04` | 110 |
| `05` | 35 |
| `06` | 75 |
| `07` | 72 |
| `08` | 3 |
| `09` | 36 |
| `10` | 24 |
| `11` | 35 |

| Metric | Count |
|---|---:|
| Record-level confirmed included-and-classified count | 451 |
| Expanded module assignment count | 562 |
| Independent `01.04` general-method bucket count | 20 |

## Remaining uncertainty

- Direct full-text / JATS access would still help determine whether the paper contains hidden disease-specific demos or stronger discovery claims.
- At the present evidence level, however, the top-level module decision is stable enough to reject `07` and remove this record from the active round-2 boundary queue.
